UPCC 15522 A Phase 2/3 Study To Evaluate The Efficacy And Safety Of Unesbulin In Unresectable Or Metastatic Relapsed Or Refractory Leiomyosarcoma
Enrolling By Invitation
99 years and younger
All
1 Location
Brief description of study
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 852149
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
